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The epidermal growth factor receptor (EGFR) is part of a large family of recep-
tors required for communicating extracellular signals through internal tyrosine
kinases. Epidermal growth factor (EGF) signaling is required for tissue develop-
ment, whereas constitutive activation of this signaling pathway is associated
with oncogenic transformation. We identified homozygous c.1283G>A
(p.Gly428Asp) mutations in the extracellular domain of EGFR in two siblings.
The children were born prematurely, had abnormalities in skin and hair, suf-
fered multisystem organ failure, and died in the neonatal period from intestinal
perforation. EGF failed to induce mutated receptor phosphorylation in patient-
derived fibroblasts and activation of downstream targets was suppressed. The
heterologously expressed extracellular domain was impaired in stability and the
binding of EGF. Cells from the affected patient undergo early senescence with
accelerated expression of b-galactosidase and shortened telomeres at all passages
when compared to controls. A comparison of homozygous inherited regions
from a separate report of a patient from the same ethnic background and EGFR
genotype confirms the pathogenicity of EGFR mutations in congenital disease.
Introduction
Epidermal growth factor receptor (EGFR, OMIM 131550)
plays critical roles in organismal development by transduc-
ing an extracellular signal to guide growth and differentia-
tion of multiple tissue types (Sibilia et al. 2007). The
disruption of EGFR in mouse model systems causes strain-
specific lethality and prominent effects upon heart, brain,
and epithelial tissues (Sibilia and Wagner 1995; Threadgill
et al. 1995; Hansen et al. 1997). Naturally occurring mouse
models with point mutations in EGFR (waved-2) have
defects in hair and eyelid opening (Luetteke et al. 1994).
Studies of the role of EGFR in organ and tissue devel-
opment have been nearly overshadowed by the discovery
of the role of activating EGFR mutations in tumor biol-
ogy (Pao and Chmielecki 2010). EGFR is overexpressed in
a range of epithelial tumor types, and somatic mutations
in EGFR were found to mediate the susceptibility of
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non-small cell lung cancer to gefitinib, a chemotherapeu-
tic that inhibits the kinase activity of EGFR (Lynch et al.
2004). Although several agents have been developed to
block EGFR activity, resistance through the activation of
alternative kinases remains a ubiquitous problem (Nied-
erst and Engelman 2013).
Investigators recently described a homozygous mutation
in the extracellular domain of EGFR (c.1283G>A
(p.Gly428Asp)) in a patient with a profound inflammatory
skin disease who died from cutaneous infection (Campbell
et al. 2014). These features mimicked dermatological com-
plications that are typically seen in patients treated with
agents that inhibit EGFR activity (Agero et al. 2006). We
report here two siblings with the identical mutation with a
related phenotype causing death in the neonatal period
from intestinal perforation. Our studies confirm that loss
of function mutations in EGFR causes a complex syndrome
with both progeroid phenotypic and cellular features.
Material and Methods
Molecular confirmation
Amplification and sequencing of exon 11 of EGFR was
performed using: 50 AGCCTCTTCGGGGTAATCAG and
50 TGCTTCTGTGTCCACTCCAG.
Downstream targets
Dermal fibroblasts from patient 2 and an unrelated con-
trol were incubated with 50 ng/mL epidermal growth fac-
tor (EGF) for 15 min. The expression of JUN, MYC, and
FOS was analyzed on 2 lg of cDNA for each sample by
real-time PCR (Applied Biosystems, Grand Island, NY,
USA). Three experiments were performed on four repli-
cates of each sample. Representative data from one exper-
iment are shown. GAPDH expression was used as a
control. Statistical significance was determined using one-
way analysis of variance.
Progeroid analysis
Telomere length was quantitated using TeloTAGGG Telo-
mere Length Assay (Roche, Basel, Switzerland) according
to the written protocol. b-galactosidase staining was per-
formed using the Senescence b-galactosidase kit (Cell Sig-
naling, Danvers, MA, USA).
Serial passaging
Dermal fibroblasts from patient 2 and a control individ-
ual were grown in Dulbecco’s Modified Eagle Medium
(DMEM) (Life Technologies, Grand Island, NY, USA),
supplemented with 10% fetal bovine serum (FBS) and
0.5% uridine. Cells were plated in triplicate at a cellular
density of 100,000 cells/well weekly from sequential pas-
sages. Cells were counted every week from passage 6 to
23.
Western blots
Nearly confluent fibroblasts were serum starved for 24 h.
Cells were incubated with EGF at a concentration of
50 ng/mL for 0, 30, or 60 min. Immunoblotting was per-
formed using EGFR antibodies at a concentration of
1:2000 (Thermo scientific, Danvers, MA, USA), and phos-
pho-EGFR antibodies at a concentration of 1:1000 (Cell
Signaling, Danvers, MA, USA).
Protein purification
Histidine-tagged sEGFRWT and sEGFRG428D were expressed
in baculovirus-infected Sf9 cells as previously described
(Ferguson et al. 2000; PMID 10970856) and purified by
nickel-NTA and size exclusion chromatography. Protein was
>80% pure by Coomassie staining.
Surface plasmon resonance
EGF was immobilized by amine coupling to an activated
CM5 surface as previously described (Ferguson et al.
2000; PMID 10970856). sEGFRWT and sEGFRG428D pro-
teins were flowed over this surface as well as a control
surface at a flow rate of 10 lL/min for 10 min, which
was sufficient to reach equilibrium even at low receptor
concentrations. The relative responses shown in Figure 5
were fit to Langmuir single-site binding isotherms in
Prism 6.0 (Graphpad, La Jolla, CA, USA).
Growth curve
Control and patient fibroblasts were plated at a cellular
density of 50,000 cells/well. Three media conditions were
used: DMEM supplemented with 10% FBS, or DMEM
supplemented with 5 lg/mL insulin, 40 ng/mL dexameth-
asone, and 50 lg/mL ascorbic acid with or without
50 ng/mL of EGF.
Variant submission
This variant has been submitted to the Leiden Online
Variant Database, a public gene variant database. This
information can be accessed at http://egfr.lovd.nl. The ref-
erence wild-type sequence is RefSeq NM_005228.3.
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Results
Patient phenotype
We evaluated two siblings from a consanguineous Roma
family. Patient 1 was born at 34 weeks gestation. She had
severe intrauterine growth restriction, nephromegaly, and
renal tubulopathy. Weight, length, and head circumference
were less than the first percentile (at 2 months weight and
head circumference were 50th percentile for 33.5 weeks’
gestation; length was 50th percentile for 32 weeks’
gestation). She had craniofacial dysmorphism with pseud-
ohydrocephalus, a progeroid appearance, striking desqua-
mation with ichthyotic, hyperpigmented, translucent skin,
absence of subcutaneous fat and sparse, stiff hair (Fig. 1A).
She had progressive abdominal distention and passed away
after intestinal perforation at 3 months of age.
Patient 2 was born at 33 weeks gestational age follow-
ing a pregnancy complicated by polyhydramnios requiring
therapeutic amniocentesis. He had ventilator-dependent
respiratory failure, grade IV intraventricular hemorrhage,
pancytopenia, liver failure, and severe intrauterine growth
retardation. His birth weight was 1195 g, and which is
less than the first percentile, as were his length and head
circumference (weight was 50th percentile for 29 weeks;
length was 50th percentile for 30.5 weeks and head cir-
cumference was 50th percentile for 31 weeks.) He had a
similar appearance to patient 1 (Fig. 1B) with apparent
macrocephaly and an inverted triangular appearance to
his face, a progeroid appearance; thin, translucent hyper-
pigmented, dry and ichthyotic skin, absence of subcutane-
ous fat, absent scalp hair, and sparse eyebrows. A skin
biopsy was performed and showed thin dermis, lympho-
cytic infiltration of hair follicles, and wiry appearing colla-
gens (Table 1).
Genomic DNA from patients 1 and 2 was analyzed by
single-nucleotide polymorphism microarrays. Two large
shared regions of homozygosity were identified; a 2.8 Mb
region on chromosome 2p (chr2:38,029,531-40,857,899)
and a 32.9 Mb region on chromosome 7 chr7: 45,297,878-
78,234,264.) Whole-exome sequencing identified four
A
B
Figure 1. Physical features of the affected siblings. The sister (A) was
photographed at 2 months of age and the brother (B) at 3 weeks of age.
Table 1. Comparison of phenotype between the patients reported here, the patient reported by Campbell et al. (2014) and the waved-2 mouse
model.
Patient 1 Patient 2 Campbell et al. Waved-2 mouse model
Polyhydramnios  + + 
Premature birth + (34 weeks) + (33 weeks) + (34 weeks) 
IUGR + + + +
Alopecia + + + +
Aged facial appearance + +  N.A.
Pseudohydrocephalus + +  
Skin desquamation + + + Abnormal skin architecture
Ichthyosis + + + N.A.
Acquired skin inflammation N.A. N.A. + +
Absent subcutaneous fat + +  
Trichomegaly   + N.A.
Nephromegaly + + + Renal malformations
Intestinal perforation + +  Susceptible to colonic injury
Recurrent vomiting/diarrhea + + + 
Recurrent infections   + 
Respiratory difficulties  + + 
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homozygous mutations between these two regions in
patient 1, as well as two shared homozygous changes out-
side of the large regions of homozygosity (Table S1).
EGFR:c.1283G>A (p.Gly428Asp) was selected for further
analysis as the other mutations lacked apparent relevance
to the phenotype.
EGF signaling is impaired in patient cell
lines
Binding of EGF by EGFR activates a sequence of receptor
tyrosine kinases and regulates nuclear transcription. Der-
mal fibroblast cell lines were generated from patient 2
and a control individual. EGF-induced expression of JUN,
FOS, and MYC were assessed using real-time PCR.
Despite robustly inducing these immediate early gene
products in control fibroblasts as expected (Fig. 2A), EGF
was not able to increase their expression in the patient-
derived cells (JUN, P = 0.0001 FOS: P < 0.0001, MYC:
P < 0.0001; Fig. 2A). Similarly, whereas EGF supplemen-
tation will allow control fibroblasts to grow in a minimal
medium containing insulin, ascorbic acid, and dexameth-
asone (IAD), EGF failed to support the growth of
patient-derived cells in the same medium (Fig. 2B and C)
– reflecting a loss of EGFR function.
Direct assessment of EGFR Function
To evaluate levels of EGFR expression and ligand-induced
activation, we probed western blots of cell lysates with
antibodies against EGFR and phospho-EGFR. EGFR levels
in the patient-derived cell line were substantially reduced
in comparison to an unaffected control (Fig. 3A, top).
Tyrosine autophosphorylation of EGFR in response to
EGF or serum addition was robust in control cells.
(Fig. 3A, bottom). but could not be detected in patient-
derived samples. This suggests that both the level and
activity of EGFRGly428Asp are strongly impaired. To con-
firm that the observed phosphorylation in control cells
was EGFR-specific, we repeated the experiment in the
presence of the EGFR inhibitor gefitinib, which entirely
inhibited phosphorylation in the control cells and lacked
any effect in the patient sample (Fig. 3B).
Previous studies have shown that EGFR levels decrease
following activation as the receptor is internalized and
degraded (Beguinot et al. 1984). We reasoned that if the
EGFR: c.1283G>A (p.Gly428Asp) mutation prevented
proper localization of EGFR or its ability to bind to EGF,
we should see no alteration of receptor levels following
administration of the ligand in the patient cells. Indeed,
whereas EGF strongly reduced the levels of EGFR at 30
and 90 minutes following stimulation of wild-type cells, it
had no detectable effect upon the EGFRGly428Asp levels
in the patient cell line (Fig. 3C). These results build upon
the previous finding that EGFRGly428Asp is mislocalized to
the cytoplasm, where it is unaffected by ligand (Campbell
et al. 2014).
EGFRGly428Asp binds to EGF with reduced
affinity in vitro
To evaluate the effect of the EGFR:c.1283G>A
(p.Gly428Asp) mutation on the ability of EGFR to bind
its ligands, we generated purified recombinant EGFR
extracellular region (sEGFR) as described and used sur-
face plasmon resonance to measure ligand binding as
described (Ferguson et al. 2000). During purification of
Figure 2. Downstream targets of EGF, Jun (dark bars), Myc (grey
bars), and Fos (light bars), are increased in response to stimulation
with EGF in control cells, but not patient cells (A). Growth of control
cells in a minimal media of insulin, dexamethasone, and ascorbic acid
(IAD) (lightest line) can be rescued with EGF treatment (IADE) (middle
line) (B), whereas patient cell growth cannot be rescued with EGF
(middle line) (C).
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the c.1283G>A (p.Gly428Asp)-mutated sEGFR variant
(sEGFRGly428Asp), it was found to run as a broad peak in
size exclusion chromatography, indicating a degree of
misfolding and aggregation. The resulting purified sEG-
FRG428D protein bound EGF approximately 100-fold more
weakly than wild-type sEGFR (Fig. 4). These data suggest
that the EGFR:c.1283G>A (p.Gly428Asp) mutation causes
EGFR’s extracellular region to fold incorrectly, consistent
with both reduced levels of the protein in patient-derived
cells (and efforts to express EGFRGly428Asp exogenously)
and loss of EGF binding. Glycine 428 is on one of the
ligand-binding domains in EGFR (domain III), but is dis-
tant from the ligand-binding site. Its substitution with an
aspartate would project that acidic residue into the
hydrophobic core of domain III, likely resulting in
impaired folding and/or stability.
Analysis of cellular senescence
Because of the progeroid appearance of the patients, we
evaluated several markers of cellular senescence. Telomere
length was shorter in patient cells as compared to con-
trols and the observed shortening of telomere length in
culture was accelerated (Fig. 5A). We evaluated the repli-
cative capacity of patient and control fibroblasts by seri-
ally passaging cells and found that the EGFRGly428Asp
patient cell line had impaired replication at late passage
when compared to control cells (Fig. 5B). Finally, we
examined senescence-associated beta-galactosidase stain-
ing. At passages where there was no notable staining in
control fibroblast cell lines we found extensive beta-galac-
tosidase expression in patient cells (Fig. 5C).
Genomic comparison to previously reported
patient
The identification of a previously undescribed mutation
in patients from the same ethnic background in this study
and that of Campbell, et al. suggests that the patients
may be related; however, there is no overlap in the pedi-
grees reported by the families, and the patient seen by
Campbell et al. (2014) was seen in Poland and the United
Kingdom, while the patients reported here have lived in
Eastern USA for multiple generations. Therefore, to fur-
ther assess relatedness, we compared exome data from
160kDa-
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Figure 3. Western blot shows higher levels of EGFR in control compared to patient samples, and higher levels of p-EGFR following EGF
stimulation in controls samples, as compared to patients (A). Addition of the EGFR kinase inhibitor gefitinib eliminates EGFR phosphorylation
following EGF stimulation and does not change overall EGFR levels (B). Levels of EGFR are decreased at 30 and 90 min following EGF stimulation























Figure 4. Binding of wild-type and G428D sEGFR to immobilized
EGF, assessed using surface plasmon resonance (SPR). Equilibrium
responses relative to a blank surface are plotted as a function of
injected receptor concentration.
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our patient 1 and the previously reported patient (Fig.
S1) We selected 75 very rare variants (<1% of the general
population) reported in our patient. We found that six of
those rare variants were shared between the two patients,
spread across several chromosomes. EGFRGly428Asp was the
only rare homozygous variant shared between the two
patients. Supporting the hypothesis of a shared ancestor,
both patient 2 and the patient reported by Campbell et al.
(2014) share a polymorphism in EGFR, which is present
in 30% of the general population. However, the shared
chromosomal region on chromosome 7 is maximally
600 KB based on the most proximal unshared mutations.
We conclude that the patients are likely related but the
common ancestors are distant.
Discussion
Receptor tyrosine kinases are used to mediate a broad
variety of extracellular to nuclear signals for growth and
differentiation. Defects in several of these proteins cause
recognizable syndromes including defects in the insulin
receptor in Donohue syndrome and NTRK1 in Type II
familial dysautonomia (Robertson et al. 2000). Evidence in
this study and in the analysis of an additional affected
patient from the same ethnic background shows that a fail-
ure of EGFR signaling leads to a complex phenotype with
marked defects in epithelial formation and gut integrity.
Based upon our evidence, we suggest that EGFRGly428Asp
has a range of defects. First, the protein has reduced stabil-
ity and binding of EGF in vitro. Second, EGF cannot stimu-
late receptor tyrosine kinase activity. Finally, the reduced
levels of EGFRGly428Asp in unstimulated cells suggest that
the protein is either unstable or localizes to a cellular com-
partment where its turnover is increased.
These findings are consistent with the previous findings
by Campbell, et al. Both this study and the previous
study found a reduced quantity of EGFR and that the
protein present is poorly stimulated, which is consistent
with either a defect in the EGF-binding domain, or cyto-
plasmic mislocalization of mutant EGFR as found by
Campbell, et al. The previous study showed an increased
amount of constitutive endocytosis, which helps explain
the low levels of EGFR. Here, we show that ligand-stimu-
lated endocytosis, a physiologic process that initiates the
EGFR signaling cascade, is decreased, which helps explain
the decreased activation of downstream targets.
It appears that the patients in our study and that of
Campbell, et al. are distantly related; however, the small
size of the shared region, the limited shared genetic mate-
rial, and the recurrence of disease in geographically distinct
members of the same ethnic group is a concerning finding,
suggesting that this mutation may be an underrecognized
cause of congenital illness in the Roma population.
During our evaluation, we considered that the patients
might phenotypically resemble other patients with Wiede-
mann-Rautenstrauch syndrome (WRS; also known as neo-
natal progeria), particularly in consideration of the facial
shape, lack of hair, hyperpigmentation, and translucent
skin. We evaluated samples from several other patients
carrying this diagnosis and did not identify mutations in
EGFR (data not shown). WRS remains a clinical diagnosis
that lacks a clear etiology and may arise from several
different genetic defects. It is possible that further studies
may show that a subset of patients with WRS have muta-
tions in EGFR and we would recommend screening
suspected patients with WRS for EGFR mutations.
Amplification or activating mutations in EGFR has
been observed in a wide range of human malignancies.
Tumors with these genetic alterations are typically
responsive to targeted therapies against EGFR, but
invariably develop resistance to anti-EGFR therapies after
exposure by the activation of alternative receptor tyrosine
Figure 5. Increased senescence is associated with the G428D
mutation as evidenced by decreased replicative capacity over serial
passages (A), increased telomere shortening over serial passages (B),
and increased beta-galactosidase staining (C).
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kinases. It is interesting to consider how developmental
pathways in affected patients may have compensated for
the loss of EGFR activity through the action of alternative
receptor tyrosine kinase. Future studies of cellular devel-
opment in the absence of EGFR signaling may provide
important clues to the pathways that are used in the
escape from EGFR inhibition.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Evaluation of 75 rare variants present in
patient 1 in the patient reported by Campbell et al. shows
multiple shared variants; only one rare variant is homozy-
gous in both patients - EGFR G428D (A). Comparison of
phenotype between our patients and the patient reported
by Campbell et al. (B).
Figure S2. Pedigree of the affected patients shows an esti-
mated coefficient of relationship of 6.25%. There is no
known relationship between these patients and the patient
reported by Campbell et al.
Table S1. Shared homozygous changes between patient 1
and patient 2. Only EGFR was selected as a putative can-
didate based on known gene function.
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